// App-Quantinova.ai

TPS595 : A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

Researchers

Presenter

  • Ciara Catherine Maria O'Sullivan

Principal Investigators

  • Karla V. Ballman

  • Linda Mackie McCall

  • Tyler J. Zemla

  • Anna Weiss

  • Melissa Mitchell

  • Victoria Susana Blinder

  • Nadine M. Tung

  • William Johnson Irvin

  • Myounghee Lee

  • Matthew P. Goetz

  • William Fraser Symmans

  • Virginia F. Borges

  • Ian E. Krop

  • Ann H. Partridge

  • Lisa A. Carey

Medical Centers

  • CCR, NIH, Bethesda, MD

  • Weill Cornell Medicine, New York, NY

  • Alliance for Clinical Trials in Oncology, Durham, NC

  • Mayo Clinic, Rochester, MN

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Beth Israel Deaconess Medical Center, Boston, MA

  • University of North Carolina, Midlothian, VA

  • University of Maryland Medical Center, Baltimore, MD

  • University of Colorado Cancer Center, Aurora, CO

  • Dana-Farber Cancer Institute, Boston, MA

  • University of North Carolina, Chapel Hill, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

  • tumor-infiltrating lymphocytes

Drug/Treatment

  • Trastuzumab emtansine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Double Blind/Blinded

  • Superiority

  • Prospective

Phase

  • III

Study Id's

  • NCT04457596

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved